Related Symbol
avatar
@Zalotie 1 month ago

Argenx (ARGX) hits 18 straight quarters of revenue growth, analysts see 23% upside

Argenx (ARGX) hits 18 straight quarters of revenue growth, analysts see 23% upside

Argenx (ARGX) is up about 14% year-to-date and Wall Street consensus points to a potential 23% upside from here. They just reported 18 consecutive quarters of revenue growth, with Q2 global product sales reaching $1.5 billion, a 60% increase from last year. The main driver right now is their Vyvgart franchise. The FDA approved a label expansion in May, making it the only approved treatment for all adult serotypes of generalized myasthenia gravis (gMG). It is also seeing traction in treating CIDP, another chronic autoimmune disorder. Looking ahead, Argenx plans to file for ocular MG treatment soon. They also have Phase 3 results coming in Q4 for empasiprubart and four more registrational studies expected next year. Most analysts rate the stock a buy. The trailing P/E is high at 36, but the PEG ratio sits at a more reasonable 1.15 based on expected growth. There is still some risk tied to upcoming clinical data, which is why at least one analyst is maintaining a hold rating, but overall sentiment remains positive.
post thumbnail
@ProduceCut309 1 month ago

18 straight quarters of growth is impressive, with Vyvgart driving strong momentum. Upcoming clinical data could be the next major catalyst for Argenx.